Prior studies have identified several anti-tumor mechanisms of metformin [336–338] with adenosine monophosphate-activated protein kinase (AMPK)-dependent PI3K/Akt/mTOR pathway inhibition considered as an important direct mechanism of metformin in treating EC [333, 339]. Here, AKT1 is linked to neoplasm.